A SECOND PHASE III MULTICENTER PLACEBO CONTROLLED STUDY OF 2 DOSAGES OF MODIFIED RELEASE TAMSULOSIN IN PATIENTS WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA-Reference-Cited by-同舟云学术

A SECOND PHASE III MULTICENTER PLACEBO CONTROLLED STUDY OF 2 DOSAGES OF MODIFIED RELEASE TAMSULOSIN IN PATIENTS WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA

Published:1998-11 Issue:5 Volume:160 Page:1701-1706
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

NARAYAN PERINCHERY¹,TEWARI ASHUTOSH¹

Affiliation:

1. MEMBERS OF UNITED STATES 93-01 STUDY GROUP; From the Divisions of Urology, University of Florida and Veterans Administration Medical Center, Gainesville, Florida

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference22 articles.

1. Pharmacological receptors in the prostate;Raz;Brit. J. Urol.,1973

2. The use of alpha-adrenergic blockers in benign prostatic obstruction;Caine;Brit. J. Urol.,1976

3. Benign prostatic hyperplasia: diagnosis and treatment;McConnell,1985

4. Pfizer Cardura BPH indication cleared February 6. The Pink Sheet, 57, T&G-1, Feb. 13, 1995.

5. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study;Fawzy;J. Urol.,1995

Cited by 182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Micro/nanofluidic device for tamsulosin therapeutic drug monitoring in patients with benign prostatic hyperplasia at point of care;Analytical Sciences;2024-03-11

2. Early investigational agents for the treatment of benign prostatic hyperplasia’;Expert Opinion on Investigational Drugs;2024-03-04

3. Therapeutic Effects of Tamsulosin in Nightmare Disorder: A Randomized, Double Blind, Placebo-Controlled, Cross-Over, Pilot Study;Drug Research;2024-01-18

4. Evaluation of Tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement;International Urology and Nephrology;2024-01-14

5. Safety and efficacy of tamsulosin 0.4 mg as an initial dose in 1,219 Korean patients with moderate to severe lower urinary tract symptoms: data from a phase IV study;Prostate International;2023-12